Health

Clinical trial indicates recovered breast cancer survivors may safely discontinue heart drugs

A study of 90 UK patients showed 98% maintained stable heart function one year after stopping precautionary cardiovascular medication.

Updated Sep 2, 2026 · 05:18 UTC1 reports

The short version

A British Heart Foundation-funded clinical trial found that breast cancer survivors whose heart function recovered can safely discontinue precautionary heart medications.
Among the 90 participants monitored across four UK hospitals, 98% who ceased medication experienced no deterioration in heart function after one year.
Patients who stopped the drugs reported an improved quality of life and reduced treatment-related side effects.
Researchers plan to track trial participants for five years to assess longer-term cardiovascular outcomes.

A clinical trial involving 90 women across four UK hospitals examined whether patients whose hearts recovered after breast cancer therapy could stop taking heart medications.[BBC News]
Researchers found that 98% of patients who ceased their heart medication maintained stable heart function after one year, with only one participant developing an issue with cardiac pumping capacity.[BBC News]
The study, led by Professor Charlotte Manisty and published in the Heart Journal, noted that participants who stopped medication reported better quality of life in surveys.[BBC News]
Approximately 15% to 20% of breast cancer cases are HER2-positive, and around 10% of patients receiving related treatments experience reduced heart function.[BBC News]

The long-term effects of stopping heart medication beyond the one-year study period remain under evaluation during a planned five-year monitoring phase.[BBC News]